Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296599 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL712399 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL31278453 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL111047 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL15368049 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL11033610 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL901213 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL31277753 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL31278068 | 0.83 | TLR4 (0.33) | TLR4 | |
| SCHEMBL6902851 | 0.83 | TLR4 (0.33) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023213922-A1 | PRECURSORS FOR THE CONTROLLED RELEASE OF α,β-UNSATURATED ALDEHYDES OR KETONES AND OTHER HIGH IMPACT FRAGRANCE SUBSTANCES | SYMRISE AG (DE) | 2023-11-09 | — | — | WO | disclosed |
| US-20150306073-A1 | THIOREDOXIN PROTEIN INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2015-10-29 | — | — | US | disclosed |
| US-5908944-A | COPPER COMPOUND CATALYST | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-01 | — | — | US | disclosed |
| US-5908945-A | COPPER COMPOUND AND SILYL REAGENT AS CATALYSTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-01 | — | — | US | disclosed |
| US-5759528-A | AMINE OXIDE SURFACTANT AND CYCLOHEXANE, CYCLOHEXENE OR CYCLOHEXANONE DERIVATIVE | INSTITUTE FOR ADVANCED SKIN RESEARCH, INC. (JP) | 1998-06-02 | — | — | US | disclosed |
| EP-0691974-B1 | ALKYLATING AGENT AND 1,4-ADDITION PROCESS OF AN ALKYL GROUP ONTO AN ALPHA, BETA-UNSATURATED KETONE COMPOUND | SCHERING AG (DE) | 1997-05-07 | — | — | EP | disclosed |
| EP-0534582-B1 | Methylation or ethylation agent and process for an 1,4-addition of a methyl- or ethylgroup to an alpha, beta-insaturated ketogroup | SCHERING AG (DE) | 1997-01-08 | — | — | EP | disclosed |
| EP-0745389-A1 | COMPOSITION FOR TOPICAL APPLICATION | INSTITUTE FOR ADVANCED SKIN RESEARCH INC. (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0691974-A1 | ALKYLATING AGENT AND 1,4-ADDITION PROCESS OF AN ALKYL GROUP ONTO AN ALPHA, BETA-UNSATURATED KETONE COMPOUND | SCHERING AG (DE) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022878-A1 | ALKYLATING AGENT AND 1,4-ADDITION PROCESS OF AN ALKYL GROUP ONTO AN ALPHA, BETA-UNSATURATED KETONE COMPOUND | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993006066-A1 | METHYLATING OR ETHYLATING AGENT AND PROCESS FOR 1,4-ADDING A METHYL OR ETHYL GROUP TO AN α,β-UNSATURATED KETO COMPOUND __ | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-04-01 | — | — | WO | disclosed |
| EP-0534582-A1 | Methylation or ethylation agent and process for an 1,4-addition of a methyl- or ethylgroup to an alpha, beta-insaturated ketogroup | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306073-A1 | THIOREDOXIN PROTEIN INHIBITORS AND USES THEREOF | TXN, TXN2, TXNL1 | TLR4 2420/4885CRBN 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.